Articles tagged with Sarcoma
Researchers at Huntsman Cancer Institute have discovered a new drug with high potential to treat Ewing sarcoma by targeting the EWS/FLI protein. The study found that an enzyme called lysine specific demethylase (LSD-1) interacts with EWS/FLI to turn off gene expression in Ewing sarcoma.
Researchers found that blocking galectin-1 in mice with established Kaposi sarcomas slowed tumor growth by suppressing blood vessel formation. This breakthrough holds promise for new treatment options for patients with KS and may also be effective for other diseases characterized by aberrant blood vessel growth.
Researchers have discovered that high levels of protein EYA3 are associated with a poor response to chemotherapy in Ewing's sarcoma patients. Lowering EYA3 levels may help increase the effectiveness of existing therapies and improve outcomes.
Pazopanib nearly tripled progression-free survival in patients with metastatic soft-tissue sarcoma whose disease has progressed following standard chemotherapy. The median follow-up was 15 months, and common side effects included fatigue, diarrhoea, and hypertension.
Moffitt Cancer Center researchers identified 39 tyrosine kinases in sarcoma cells, which could drive tumor growth and survival. These enzymes were found to be expressed in multiple tumors, potentially limiting the effectiveness of targeted agents.
Researchers found that viral lytic replication impairs the effectiveness of Nutlin-3, a targeted therapy for KSHV-induced lymphomas. The study suggests reactivating p53 as a selective treatment modality.
A combination of cixutumumab and temsirolimus shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, with two achieving complete responses. The study suggests that managing side effects is vital to maintaining the therapy and slowing disease progression.
Researchers discovered a novel viral oncogenesis mechanism in which KSHV co-opts cellular signaling pathways and modifies the microenvironment for viral replication. The virus induces EndMT, giving rise to infected invasive cells, allowing efficient spread of the virus.
Researchers at Moffitt Cancer Center found MK1775 effective in treating sarcoma cells, inducing apoptosis and causing cell death, regardless of p53 mutation status. The study suggests that Wee1 inhibition by MK1775 may represent a novel approach in treating sarcomas.
Researchers at Joslin Diabetes Center have identified two major molecular signaling pathways that regulate cell growth and division, hallmarks of cancer biology. The study provides new candidate targets for treating soft-tissue sarcomas, which can be controlled but not cured by current treatments.
Researchers from Yale University discovered that a virus from the same family as rabies can target and kill soft tissue sarcomas. The oncolytic activity of VSV-rp30a was found to be effective against 12 out of 13 different sarcoma lines, with resistance overcome by interferon antagonizers.
23andMe has completed its Independent Sarcoma Scientific Advisory Committee, comprising leading researchers and clinicians, to advance understanding of sarcomas. The company aims to combine genetic data with patient-reported outcomes to find patterns in sarcoma biology and treatment response.
Researchers have made a breakthrough in Ewing's sarcoma treatment with the discovery of a novel small molecule that blocks key protein interactions. The $4.37 million NCI grant will fund preclinical toxicology studies to accelerate the development process.
Researchers at TGen have identified two potential anti-cancer drug targets, STK10 and TNK2, for Ewing's sarcoma in children. These kinases play a crucial role in the growth and survival of cancer cells, making them promising therapeutic targets.
Researchers at the University of Leeds have identified PYM as a key protein involved in the replication and spread of Kaposi's Sarcoma-causing viruses. Blocking interactions between PYM and viral proteins could lead to new treatment options for this disease.
Researchers found that combining regional hyperthermia with chemotherapy increases local progression-free and disease-free survival rates in high-risk sarcoma patients. The treatment has shown promise, but the safety profile remains a concern.
Researchers at the ESMO Conference on Sarcoma and GIST discuss exciting new science on rare tumors found in muscle, blood vessels, deep skin tissues, nerves, and joints. Novel treatments are emerging for a large number of sarcoma types, targeting initial molecular alterations driving these tumors.
Scientists have identified CD99 as a crucial marker in Ewing sarcoma development and suggest targeting it to develop new therapies. The protein's role is tied to preventing neural differentiation, a process that contributes to oncogenesis.
Researchers have found that figitumumab has antitumor activity in Ewing's sarcoma, a cancer commonly affecting male teenagers. The drug targets the insulin-like growth factor signalling pathway, and initial studies have shown safety and efficacy in patients with refractory Ewing's sarcoma.
Researchers at UCLA's Jonsson Comprehensive Cancer Center found that the loss of PTEN tumor suppressor gene plays a central role in transforming benign neurofibromas into malignant and deadly sarcomas. The study could lead to new therapies targeting cell signaling pathways regulated by PTEN.
Researchers at University of Utah Health have made a surprising connection between high levels of GSTM4 protein and poor chemotherapy response in Ewing's sarcoma patients. The study suggests that targeting GSTM4 could lead to more effective treatments for individual patients.
A large analysis found Caucasians are nine times more likely to be diagnosed with Ewing's sarcoma than African Americans. Additionally, men are more likely to die from the disease than women among Caucasians. The study highlights racial and gender differences in incidence and survival rates.
Primary pancreatic MFH is a rare entity with distinct clinical characteristics, requiring prompt diagnosis for effective treatment. Characteristic imaging findings include large, liquescent-necrosis masses or multilocular cystic lesions with calcification on CT scans.
A new treatment combination using a genetically altered herpes virus and chemotherapy drug reduces tumor size in mice with aggressive human sarcoma. The therapy appears to be well-tolerated, but further development is needed before clinical trials can begin.
A new study found that combining reishi mushroom and green tea extracts creates a synergistic effect to inhibit tumor growth and delay death in mice with sarcomas. The combination reduced tumor weight by 45% compared to treatment with only reishi, confirming the synergy of the two substances.
A UCLA study found PET scanning more sensitive and accurate than conventional imaging methods in detecting treatment response in sarcoma patients. Standard size-based evaluation methods only identified 20% of responders, while PET accurately picked up all responders.
A new study found significant racial and ethnic differences in the treatment and survival of patients with extremity soft-tissue sarcomas. Blacks had lower rates of surgeries that would have saved their arm or leg, higher death rates, and were least likely to receive additional treatments for improved survival.
A phase III study of 341 high-risk patients with deep, local sarcomas shows significant improvement in tumour response and survival rates when treated with a combination of chemotherapy and local, deep hyperthermia. The combined therapy has been applied to patients before surgery, demonstrating its effectiveness.
A study published in the Journal of the National Cancer Institute found that nearly 80% of Kaposi sarcoma tumors arose independently from multiple cells. This challenges the traditional understanding of cancer origins, suggesting that Kaposi sarcoma is not a true metastatic cancer.
Patients treated at high volume centers have better 30-day and 5-year survival rates compared to those at low volume centers. High-grade tumors and larger tumor sizes are less common in high volume centers, yet outcomes remain superior.
A retrospective study found that trabectedin response rates were significantly higher than previous studies, with an overall response rate of 51% and a progression-free survival rate of 88%. This suggests that myxoid sarcoma may be a uniquely sensitive subgroup to trabectedin treatment.
Scientists have developed a mouse model for synovial sarcoma, revealing that the tumor arises from skeletal muscle precursor cells called myoblasts. The study also showed that expression of a chimeric fusion protein called SYT-SSX in these cells is sufficient to induce synovial sarcoma with 100% penetrance.
Researchers found a significant increase in soft tissue sarcoma cases among hereditary retinoblastoma survivors, with leiomyosarcoma being the most common subtype. Regular medical surveillance is crucial for these patients to detect potential cancers early.
Researchers identified a shared causative mechanism among malignant melanoma, soft-tissue sarcomas, and pediatric renal carcinoma, suggesting a common therapeutic strategy. The discovery centers on the MiT transcription factor family, which regulates growth genes and is abnormally expressed in these cancers.
Ewing's sarcoma treatment strategy proposed by Georgetown University Medical Center researchers, targeting EWS-FLI1 and helicase protein interaction to promote cancer development.
Researchers found that inhibiting heme oxygenase-1 activity reduces tumor growth in mice with Kaposi's sarcoma lesions. The study offers a potential new treatment for the disease.
Researchers have discovered a major gateway for KSHV entry into human cells, suggesting the virus may facilitate its own infectivity by inducing stress responses. This finding has significant implications for understanding Kaposi's sarcoma and developing new treatments.
A new study demonstrates high rates of tumor death in patients receiving a preoperative chemotherapy and radiation regimen, suggesting a promising approach for treating high-grade soft tissue sarcomas. The regimen has been associated with significant but manageable toxicity and modest wound complication rates.
Children with childhood soft tissue sarcomas have a six-fold increased risk of developing a second cancer, with absolute risks estimated at approximately 3% by age 20. The risk is highest within the first five years post-treatment, particularly for females and those treated with radiation or chemotherapy.
Participation in cancer clinical trials improves survival, with significant benefits for Kaposi Sarcoma patients. Young adults with sarcomas face limited treatment options and low clinical trial participation rates, contributing to poor survival rates.
Researchers found that high-dose-rate brachytherapy after surgery improved limb-sparing outcomes for soft-tissue sarcoma patients. Five-year survival rates reached 83%, with significant reductions in tumor recurrence and metastasis.
A study published in Radiology found that MRI can accurately detect bone invasion by soft-tissue sarcomas, with a sensitivity and specificity of 100% and 93%, respectively. This accuracy enables radiologists to confidently evaluate MR results for bone involvement, previously reserved for soft tissue involvement.
A new study found that Gleevec significantly reduced Kaposi's sarcoma lesions in five HIV-positive patients, with one patient experiencing a 90% regression. The therapy targets cancer cells and eliminates debilitating side effects associated with chemotherapy.
Researchers found imatinib inhibited tumor growth and cell proliferation in mice with human Ewing's sarcoma tumors, offering a potential new therapy for the disease. Higher concentrations of imatinib were needed to kill Ewing's sarcoma cells than other tumor cells.
Researchers develop genetic fingerprint technique to distinguish between various subtypes of adult soft-tissue sarcomas, leading to improved diagnosis and targeted therapies. The technology also helps predict patient outcome and resistance to treatment.
A UNC scientist found that trauma and human herpesvirus 8 (HHV8) contribute to the development of Kaposi's sarcoma, a cancer linked to HIV. The researcher also discovered that HHV8 can be detected in saliva prior to disease development, suggesting new treatment possibilities for high-risk individuals.
Researchers at Memorial Sloan-Kettering Cancer Center developed a nomogram to predict sarcoma patient outcomes, combining age, tumor size, and other factors to provide more accurate prognosis. The tool enables doctors to tailor treatments based on individual patient risk, potentially leading to better outcomes.
Researchers successfully used isolated limb perfusion to treat 51 patients, saving 44 limbs and enabling radical resection of residual tumors. Patients maintained over 80% of pre-operative activities post-surgery.
Human herpes virus 8 (HHV-8) is linked to Kaposi's sarcoma, a cancer often seen in people with compromised immune systems. Deep kissing and amyl nitrite use are risk factors for infection, according to a study published in the New England Journal of Medicine.
A UC San Francisco study published in the New England Journal of Medicine found that HHV-8 is a direct cause of Kaposi's sarcoma in HIV-positive homosexual men, with transmission through sexual contact playing a major role. The study showed that infection with HHV-8 increases the risk of developing Kaposi's sarcoma within 10 years.